NCT05908032View on ClinicalTrials.gov

Study of CM310 in Subjects With Allergic Rhinitis

PHASE3CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

August 10, 2023

Primary Completion Date

December 4, 2023

Study Completion Date

December 4, 2023

Conditions
Allergic Rhinitis
Interventions
BIOLOGICAL

CM310

IL-4Rα monoclonal antibody

BIOLOGICAL

Placebo

Placebo

Trial Locations (1)

Unknown

Beijing Tong-Ren hospital, Beijing

Sponsors
All Listed Sponsors
lead

Keymed Biosciences Co.Ltd

INDUSTRY

NCT05908032 - Study of CM310 in Subjects With Allergic Rhinitis | Biotech Hunter | Biotech Hunter